Chronic hepatitis B
Conditions
Interventions
TMF sequential treatment group:Adefovir (TMF) sequential therapy
TAF maintenance treatment group:Tenofovir alafenamide (TAF) maintenance therapy
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.HBsAg positive for at least 6 months before enrollment; 2. HBeAg negative; 3.The serum HBV-DNA is between 10-100 IU/mL, and the serum ALT is within the normal range 4.Transient imaging of liver elasticity confirmed the presence of advanced liver fibrosis (9 kPa = LSM<12 kPa); 5. Prior to enrollment, only TAF antiviral therapy was used and no anti liver fibrosis drugs were used; 6.The diagnosis of CHB meets the diagnostic criteria of the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)"; 7.Voluntarily participate in the study and promise to cooperate in completing the follow-up.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating women; 2. Age under 18 years old or over 65 years old; 3.Merge other viral infections such as hepatitis virus, CMV, EBV, and HIV; 4. Combining alcoholic, metabolic, drug-induced, or autoimmune liver diseases; 5.Patients with cirrhosis, liver cancer, and liver transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| alpha-fetoprotein;HBsAg Loss;HBV DNA seroconversion rate;HBV RNA seroconversion rate;Liver Stiffness Measurement;Hemoglobin;White Blood Cell Count;Platelet Count; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life Rating;Adverse reaction;Alanine aminotransferase;Bilirubin metabolism;Albumin;Prothrombin time;Serum creatinine;Estimated glomerular filtration rate; | — |
Countries
China
Contacts
Public ContactEnqiang Chen
West China Hospital, Sichuan University
Outcome results
None listed